recombinant human collagen Type VII

**Recombinant human collagen Type VII (rC7)** is a recombinant protein therapy designed to replace the deficient type VII collagen in recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic skin disorder caused by mutations in the *COL7A1* gene. This full-length protein incorporates into the dermal-epidermal junction (DEJ) basement membrane zone (BMZ) to form anchoring fibrils, restoring skin integrity, reducing blistering, fragility, and scarring. Preclinical studies demonstrated efficacy via intradermal, intravenous, and topical administration in RDEB mouse models, with sustained BMZ incorporation for months, accelerated wound healing, reduced fibrosis through TGF-β isoform modulation, and prolonged survival. Produced from gene-corrected fibroblasts or CHO cells, it shows promise for protein replacement therapy in RDEB, though antibody formation was noted in mice (preventable by immunosuppression).[1][2][3][4][9]

Other names

recombinant human type VII collagenrecombinant C7rC7rC-7rC 7recombinant human type VII pro-collagenrecombinant human collagen alpha-1 (VII) chain homo-trimer